The acquisition of Theravance Biopharma adds a durable, cash-generative COPD asset, YUPELRI, and multiple value streams to the portfolio, funded through non-recourse financing and expected to be accretive post-closing. Integration will focus on cost synergies and leveraging existing infrastructure…
The acquisition of Theravance Biopharma adds a durable, cash-generative COPD asset, YUPELRI, and multiple value streams to the portfolio, funded through non-recourse financing and expected to be accretive post-closing. Integration will focus on cost synergies and leveraging existing infrastructure.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
